Effect of valsartan on renal handling of uric acid in healthy subjects

Journal of Nephrology

Volumn 13, Issue 2, 2000, Pages 126-128

  González Ortiz, Manuel ^a   Mora Martínez, José Miguel ^a   Martínez Abundis, Esperanza ^a   Balcázar Muñoz, Blanca Rebeca ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

AT1 receptor antagonist; Renal handling of uric acid; Uric acid excretion; Valsartan

Indexed keywords

VALSARTAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; NORMAL HUMAN; SINGLE BLIND PROCEDURE; URIC ACID URINE LEVEL; URINARY EXCRETION; URINE FLOW RATE;

ADULT; FEMALE; HUMANS; KIDNEY; MALE; SINGLE-BLIND METHOD; TETRAZOLES; URIC ACID; VALINE;

EID: 1642586738     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994; 47: 586-98.
2. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7.
3. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-5.
4. Tsunoda K, Abe K, Hagino T, Omata K, Misawa A, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a non-peptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32.
5. Van den Meiracker AH, Admiraal PJJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In't Veld AJ. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9.
6. Müller P, Flesh G, De Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997; 52: 441-9.
7. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subjects: evidence for a 4-component system. Ann Rheum Dis 1980; 39: 173-9.
8. Diamond HS. Interpretation of pharmacologic manipulation of urate transport in man. Nephron 1989; 51: 1-5.
9. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59: 364-8.
10. Brand FN, McGee DL, Kannel B, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11-8.
11. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.
12. Madrid MI, García-Salom M, Tornel J, De Gasparo M, Fenoy FJ. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis. Am J Physiol 1997; 273: R1676-82.
13. Mann JF. Valsartan and the kidney: present and future. J Cardiovasc Pharmacol 1999; 33 (suppl 1): S37-40.